Insights In IPF Logo
Contact Us   
  • About IPF
    • Introduction to IPF
    • Epidemiology of IPF
    • Disease Course of IPF
    • AE-IPF (Acute Exacerbations of IPF)
    • Costs of IPF
    • Risk Factors for IPF
    • Molecular Understanding of IPF
    • Insights in IPF Podcast Series 
  • IPF Guidelines
    • Annotated IPF Guidelines
    • Annotated IPF Guidelines: Management of IPF
    • ATS Guidelines 
  • Diagnosing IPF
    • Diagnostic Criteria and Diagnostic Algorithm
    • Clinical Features
    • Radiology Features
    • Histopathology Features
    • Multidisciplinary Approach to Diagnosis of IPF
  • Managing Patients
    • IPF Symptom Management
    • Managing the comorbidities
    • Building/Managing the support system
  • Clinical Corner
    • Auscultation
    • HRCT
    • Histopathology
    • GAP Model for Predicting Mortality Risk
  • Reading Room
    • News and Views
    • Suggested Reading
  • IPF Radiology Rounds
  • News and Views
  • Suggested Reading

Learn about prescription IPF treatment

Learn More

  • About IPF
    • Introduction to IPF
    • Epidemiology of IPF
    • Disease Course of IPF
    • AE-IPF (Acute Exacerbations of IPF)
    • Costs of IPF
    • Risk Factors for IPF
    • Molecular Understanding of IPF
    • Insights in IPF Podcast Series 
  • IPF Guidelines
    • Annotated IPF Guidelines
    • Annotated IPF Guidelines: Management of IPF
    • ATS Guidelines 
  • Diagnosing IPF
    • Diagnostic Criteria and Diagnostic Algorithm
    • Clinical Features
    • Radiology Features
    • Histopathology Features
    • Multidisciplinary Approach to Diagnosis of IPF
  • Managing Patients
    • IPF Symptom Management
    • Managing the comorbidities
    • Building/Managing the support system
  • Clinical Corner
    • Auscultation
    • HRCT
    • Histopathology
    • GAP Model for Predicting Mortality Risk
  • Reading Room
    • News and Views
    • Suggested Reading
  • IPF Radiology Rounds

News & Views

Browse top-line reviews of recently-published, newsworthy articles relevant to the IPF community, with a focus on those with potential implications for patient care.

  • About IPF
    • Is telomere length associated with survival in IPF?
    • How can mortality risk be assessed in patients with IPF?
    • Could periostin be a viable biomarker for IPF?
    • Are acute exacerbations driven by cellular mechanisms?
    • What are the outcomes of combined pulmonary fibrosis and emphysema in patients with IPF?
    • How does the lung microbiome change during acute exacerbation?
  • Diagnosing IPF
    • Can CT lung cancer screening also detect IPF?
    • Can biomarkers help distinguish combined IPF and emphysema from IPF alone or emphysema alone?
  • Managing IPF
    • How should cough be treated in patients with IPF?
    • Should all patients with IPF be treated for GER?
    • What do patients with IPF want in pulmonary rehab education?
    • Should all patients with IPF be treated with antacid medications?
    • Can exercise training impact outcomes in patients with IPF?
    • Should patients with IPF undergo mechanical ventilation for respiratory failure?
    • Is daily home spirometry an effective tool for detecting disease progression in IPF?
  • Privacy Notice
  • Terms of Use
  • Contact Us
  • Site Map

Copyright 2021, Boehringer Ingelheim, Inc. All rights reserved. Use of this site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Policy. (3/21)

Boehringer Ingelheim Logo

PC-US-119781

You’re leaving this website

You are now leaving a Boehringer Ingelheim Pharmaceuticals, Inc. site. Boehringer Ingelheim Pharmaceuticals, Inc. has not reviewed the contents of all pages and sites that may be linked to this site. Boehringer Ingelheim Pharmaceuticals, Inc. is not responsible and disclaims any liability for the content of any other page or site or for any viruses or similar harmful programs that may be present on such pages or sites. Linking to any other page or site is at your own risk.

Continue    Stay on this site